Evidence map›Paper›PMID 39207259›Full record

Observational studyThe Journal of infectious diseases2025

Galectin 9 Levels as a Potential Predictor of Intact HIV Reservoir Decay.

Sergio Serrano-Villar, Akshay Gala, Peter Bacchetti, Rebecca Hoh, Clara di Germanio, Lillian B Cohn, Timothy J Henrich, Peter W Hunt, Gregory M Laird, Satish K Pillai and 2 more

Abstract readObservational Study
In one paragraph

Observational study in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sergio Serrano-VillarDivision of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, Zuckerberg San Francisco General Hospital, and University of California San Francisco.ORCID 0000-0002-5447-3554
Akshay GalaVitalant Research Institute and University of California San Francisco.
Peter BacchettiDepartment of Epidemiology and Biostatistics, University of California San Francisco.
Rebecca HohDivision of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, Zuckerberg San Francisco General Hospital, and University of California San Francisco.
Clara di GermanioVitalant Research Institute and University of California San Francisco.
Lillian B CohnVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Timothy J HenrichDivision of Experimental Medicine, Department of Medicine, Zuckerberg San Francisco General Hospital, and University of California San Francisco.
Peter W HuntDivision of Experimental Medicine, Department of Medicine, Zuckerberg San Francisco General Hospital, and University of California San Francisco.
Gregory M LairdAccelevir Diagnostics, Baltimore, Maryland.
Satish K PillaiVitalant Research Institute and University of California San Francisco.
Steven G DeeksDivision of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, Zuckerberg San Francisco General Hospital, and University of California San Francisco.
Michael J PelusoDivision of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, Zuckerberg San Francisco General Hospital, and University of California San Francisco.

Funding

Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Delaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0M
Viral reservoirs and sanctuaries in HAART - treated patients: role and mechanismsU19AI096109 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEEKS, STEVEN GRANT · 2011 to 2015
$29.5M
Centralized Resource to Accurately Quantify Latent and Expressed HIV ReservoirsU24AI143502 · NIAID · ACCELEVIR DIAGNOSTICS, LLC · PI LAIRD, GREGORY MICHAEL, MARTIN, ALBINE · 2020 to 2024
$4.9M
Centralized Resource to Accurately Quantify Latent and Expressed HIVReservoirsR24AI143502 · NIAID · ACCELEVIR DIAGNOSTICS, LLC · PI Gregory Michael Laird, Albine Martin · 2025 to 2026
$2.1M
A Novel Test to Measure Latent Virus in HIV-1 Infected PatientsR44AI124996 · NIAID · ACCELEVIR DIAGNOSTICS, LLC · PI LAIRD, GREGORY MICHAEL · 2018 to 2019
$2.0M
Characterizing the virologic and immunologic signatures of HIV exceptional controlK23AI157875 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PELUSO, MICHAEL JOSEPH · 2021 to 2025
$927k
Mentoring Scientists for Careers in HIV Translational Clinical ResearchK24AI174971 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Timothy Jensen Henrich · 2023 to 2026
$766k
amfAR InstituteBeat-HIV CollaboratoryBill and Melinda Gates FoundationDARE Collaboratory AI096109I4C CollaboratoryInstituto de Salud Carlos III ICI20/00058NIAID NIH HHS K23 AI157875NIAID NIH HHS K24 AI174971NIAID NIH HHS P30 AI027763NIAID NIH HHS R24 AI067039NIAID NIH HHS R24 AI143502NIAID NIH HHS R44 AI124996NIAID NIH HHS U19 AI096109NIAID NIH HHS U24 AI143502NIAID NIH HHS UM1 AI164560NIH HHS K23 A137522, K23 AI157875, U24AI143502, R44AI124996University of California San Francisco
6 · The paper itself

Abstract

backgroundDuring antiretroviral therapy (ART), the HIV reservoir shows variability, with cells carrying intact genomes decaying faster than those with defective genomes, particularly in the first years. The host factors influencing this decay remain unclear.

methodsObservational study of 74 PWH on ART, 70 (94.6%) of whom were male. Intact proviruses were measured using the intact proviral DNA assay, and 32 inflammatory cytokines were quantified using Luminex immunoassay. Linear spline models assessed the impact of baseline cytokine levels and their trajectories on intact HIV kinetics over seven years.

resultsBaseline Gal-9 was the strongest predictor, with lower levels predicting faster decay. A 10-fold decrease in baseline Gal-9 correlated with a 45% (95% CI, 14%-84%) greater annual decay of intact HIV genomes. Higher baseline interferon-inducible T-cell α chemoattractant (ITAC), interleukin 17 (IL-17), and macrophage inflammatory protein 1α (MIP-1α) levels also predicted faster decay. Longitudinal increases in MIP-3α and decreases in IL-6 were linked to a 9.5% and 10% faster decay, respectively.

conclusionsThe association between lower baseline Gal-9 and faster intact HIV decay suggests targeting Gal-9 could enhance reservoir reduction. The involvement of MIP-3α and IL-6 highlights a broader cytokine regulatory network, suggesting potential multi-targeted interventions.

Indexed as

GalectinsHIV-1HIV InfectionsAdultCytokinesFemaleHumansLongitudinal StudiesMaleMiddle AgedProvirusesViral LoadCytokinesGalectinsLGALS9 protein, humancytokinesgalectin 9HIV persistenceHIV reservoirinflammation

Identifiers

PMID39207259
PMCPMC11793034

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.